Solta Medical, Inc., a division of Valeant Pharmaceuticals, is a global leader in the aesthetic energy-based device industry, providing innovative, effective solutions for patients; each designed to enhance and expand our partner physicians’ medical practices. With over a decade at the forefront of the industry, we’ve marked some important milestones. Take a look back at our company’s history by selecting a timeline item.
Select a timeline item below.
January, 2014 - Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Solta Medical on January 23, 2014. Solta Medical will retain its name and its product offering will be integrated into Valeant’s aesthetics portfolio.
February, 2013 - Solta acquires privately-held Sound Surgical Technologies, adding complementary surgical and non-invasive product lines to Solta’s broad portfolio of leading aesthetic brands. Surgical body contouring products include the popular VASERlipo™ system, which uses ultrasound waves to selectively emulsify fatty tissue prior to extraction from the body. VASERsmooth™, PowerX®, VentX® and Origins round out the surgical brand offerings, while VASERshape™, a non-invasive approach to reduce cellulite, rounds out the array of aesthetic body treatments.
May, 2013 - Solta announces the Thermage® Total Tip 3.0, a highly effective treatment tip for face and neck as well as other body treatments that offers the earliest visible results in Thermage treatment history in addition to the consistent long-term results. Targeted, uniform, bulk heating allows dermatologists to treat patients effectively while maintaining patient comfort.
June, 2013 - Solta announces Isolaz® 2, the next generation acne therapy device. Isolaz 2 effectively targets the root causes of acne through a unique, clinically proven combination of vacuum extraction for deep pore purification, broadband light to destroy acne causing bacteria, and a profusion mode to enhance the delivery of topicals into the skin.
June, 2013 - Solta announces that it has received a new FDA 510(k) clearance of its Fraxel® DUAL 1550/1927 laser system for the treatment of pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephelides (freckles). The Fraxel DUAL system is an unsurpassed breakthrough skin resurfacing technology that renews skin and helps maintain skin's youthful glow despite a person's age or skin color, with minimal discomfort and downtime.
May 2012 - Solta Medical announced the availability of the Fraxel re:pair® SST Laser Platform in the United States. The updated platform addresses the major needs of aging and sun-damaged skin and offers physicians unmatched versatility and customization to treat a broad range of clinical indications. It also offers patients a fast, single-pass, single-treatment option providing impressive resurfacing results with more comfort and reduced healing time compared to a traditional Fraxel re:pair treatment.
August 2012 - Solta Medical announced an exclusive partnership with SkinCeuticals to deliver the first fractional laser treatment plus in-office and home use antioxidant skincare regimen. The partnership is the culmination of clinical research supported by Solta and SkinCeuticals exploring the beneficial effects of using Solta´s Clear + Brilliant® Laser System with its new handpiece named Perméa® and SkinCeuticals widely popular C E Ferulic® antioxidant.
February, 2011 - Solta introduces Clear + Brilliant® which creates and defines an entirely new category of laser aesthetic treatments designed to attract younger patients looking to take control of their aging process. Clear + Brilliant provides a new option for physicians and skin care providers to address evolving consumer needs.
November, 2011 - Solta acquires Liposonix®, adding another innovative technology to Solta Medical’s portfolio of products. Liposonix and its High Intensity Focused Ultrasound (HIFU) technology represent a unique technology in the fat ablation market, and complement the technology of the Thermage and Fraxel product lines.
October 2010 – Solta acquires CLRS Technology Corporation, the developer, manufacturer and marketer of the CLARO personal care acne treatment device, giving Solta direct access to an already marketed and FDA cleared consumer medical device.
February 2010 – Solta acquires privately held Aesthera Corporation and its proprietary Isolaz product line for the treatment of acne conditions that impact an estimated forty–to–fifty million individuals in the U.S. annually.
January 2009 – new corporate name Solta Medical, Inc. introduced as an "umbrella" corporate identity over a house of aesthetic brands.
August 2010 - Solta Medical announced approval of its Thermage CPT™ system. In the fall of 2009, the company received U.S. FDA clearance to market and sell the Thermage CPT system and now in Canada. The system is now available in over 100 countries worldwide. The Thermage CPT system represents a significant advancement in radiofrequency technology for the treatment of wrinkles and demonstrates Solta Medical's deep commitment to deliver cutting edge, innovative products to the anti-aging market.
August 2009 - Solta Medical announced the Fraxel re:store® Dual system, providing superior results for large body areas during a single treatment. Prior to the non-ablative Fraxel re:store Dual system, laser skin resurfacing procedures were largely limited to the face. The Fraxel re:store Dual takes the industry leading fractional laser technology to the next level by adding a novel 1927 nm wavelength, the first ever application of a Thulium laser in the aesthetics market, optimized for treatment of pigmentation and other superficial skin conditions.
December 2008 – Thermage® acquires Reliant Technologies, Inc., bringing together the Thermage product line and Reliant’s Fraxel line of proprietary fractional laser technology.
By 2008 ThermaCool had received a series of indications expanding treatment to all parts of the body: In 2008 - Temporary improvement in the appearance of cellulite. In 2007 - Non-invasive treatment of the upper/lower eyelids. In 2005 - Non-invasive treatment of wrinkles & rhytids (expanded to off-face indications). In 2004 - Non-invasive treatment of facial wrinkles & rhytids. In 2002: Non-invasive treatment of periorbital wrinkles & rhytids.
February 2007 – Thermage introduced the ThermaCool® NXT, its next generation system for non-invasive skin tightening and contouring. With improvements inside and out, the industry-leading ThermaCool system has been redesigned to save time, reduce procedure cost, simplify the treatment experience and improve clinician comfort. ThermaCool NXT allows physicians to perform more procedures in less time while providing more flexibility and greater ease of use than ever before.
November 2006 – Thermage, Inc. goes public in an initial public offering and begins trading on the NASDAQ Global Market.
Thermage®, an innovative, non-invasive radiofrequency (RF) procedure for the non-invasive treatment of wrinkles. Thermage was the first aesthetic energy device company to successfully employ a recurring revenue model from disposable treatment tips.
ThermaCool receives initial indication for dermatologic and general surgical procedures for electrocoagulation and hemostasis.
The Company incorporates as Thermage, Inc. and begins research and development of the ThermaCool device.
A story of innovation and partnership at Solta Medical
As we grow, we're always looking for great candidates
Find opportunities to get to know us better
Except as otherwise indicated, all product names, slogans and other marks are trademarks of the Valeant family of companies.
© 2014 Solta Medical, a division of Valeant Pharmaceuticals North America, LLC. All rights reserved.
25881 Industrial Blvd.
Hayward, CA 94545 USA
U.S. Toll free: 1-877-782-2286
11818 North Creek Pkwy North
Bothell, WA 98011
357 McCaslin Blvd., Suite 100
Louisville, CO 80027-2932
+31 206 537 060
Solta Medical International BV
+61 02 9999 1081 (in Au)
+61 2 9999 1081 (Outside Au)
Level 1, Tower 1, STE 1.3
394 Lane Cove Road
+852 2145 2533
Solta Medical International Limited
RM 1412, Cosco Tower,
183 Queen�s Road Central,
Maniera Bldg 9F, 2-10-8
+44 208 200 2336
468 Church Lane
London, United Kingdom
This website has been developed by Solta Medical, Inc. to provide general information about its devices and its technology. The information contained in this website is not intended to provide medical advice. Access and use of this website is subject to the terms and conditions set forth herewith and all applicable laws, statutes, and/or regulations. Solta Medical may revise these terms and conditions from time to time by updating this posting.
Solta Medical authorizes you to copy documents or pages published by us on this website for your noncommercial reference use only, provided any copy you make retains all copyright or other proprietary notices and any disclaimers contained herein. If you link to any other websites from this site, you should follow the copyright provisions contained in those sites.
Please be aware that Solta Medical actively and aggressively enforces its intellectual rights to the fullest extent of the law.
While Solta Medical intends to periodically update this website, it makes no representations or warranties as to its accuracy or completeness. Access to and use of the content is solely at your own risk; neither Solta Medical, nor any party involved in creating or delivering this website shall be liable for any damage of any kind arising out of the access, use, or the inability to access or use this site, or for any omissions or errors contained in the website.
Certain links on this website lead to resources maintained by others over whom Solta Medical has no control. As such, Solta Medical does not adopt, endorse, opine, or make any representation as to the truth, accuracy, legality, or any other aspect of the information contained in those resources.
Last updated: January 2009.
Medical Google+ Page - Germany